---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-010086"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2022-03-14T23:59:59+00:00"
generated_at: "2026-06-26T23:06:54.519103+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma posts $107.9M cash; FDA path for efzofitimod registrational trial in Q3 2022

## Summary
- Cash, cash equivalents and investments of $107.9M as of Dec 31, 2021.
- FDA End-of-Phase 2 meeting provides development pathway; registrational trial for efzofitimod in pulmonary sarcoidosis planned to start Q3 2022.
- Orphan drug designation granted for efzofitimod in sarcoidosis.
- ATYR2810 Phase 1 study expected to initiate in H2 2022.
- R&D expenses $23.3M in 2021, expected to increase in 2022.

## SEC filing metadata
- accession: 0001564590-22-010086
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2022-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000156459022010086/0001564590-22-010086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000156459022010086/life-8k_20220314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-010086
- JSON: https://secwatch.observer/filing/0001564590-22-010086.json
- Plain text: https://secwatch.observer/filing/0001564590-22-010086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.